Management of the Hospitalized Transplant Patient

Current Diabetes Reports

Volumn 15, Issue 4, 2015, Pages

  Boerner, Brian ^a   Shivaswamy, Vijay ^a   Goldner, Whitney ^a   Larsen, Jennifer ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplant; Diabetes complication; Diabetes mellitus type 1; Diabetes mellitus type 2; Heart transplant; Hyperglycemia; Kidney transplant; Organ transplant; Rejection

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; METFORMIN; RAPAMYCIN; TACROLIMUS; GLUCOSE BLOOD LEVEL;

BONE MARROW TRANSPLANTATION; CORTICOSTEROID THERAPY; DIABETES MELLITUS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INSULIN RESISTANCE; INSULIN TREATMENT; INTESTINE GRAFT; INTESTINE TRANSPLANTATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; PATIENT CARE; POST TRANSPLANT DIABETES MELLITUS; REVIEW; TOTAL PARENTERAL NUTRITION; ADVERSE EFFECTS; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; METABOLISM; POSTOPERATIVE CARE; RISK FACTOR; TRANSPLANTATION;

BLOOD GLUCOSE; DIABETES MELLITUS; HOSPITALIZATION; HUMANS; POSTOPERATIVE CARE; RISK FACTORS; TRANSPLANTATION;

EID: 84923770394     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-015-0585-6     Document Type: Review

References (81)

1. Pei D, Chen TW, Kuo YL, et al. The effect of surgical stress on insulin sensitivity, glucose effectiveness and acute insulin response to glucose load. J Endocrinol Investig. 2003;26:397–402.
2. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75:SS3–24.
3. Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14:1992–2000. Recommended changes in diagnosis of post-transplant diabetes and update in current contributing causes.
4. Chakkera HA, Knowler WC, Devarapalli Y, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol: CJASN. 2010;5:1669–75.
5. Hecking M, Haidinger M, Doller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol: JASN. 2012;23:739–49. Evidence suggesting early glucose control in hospitalization for kidney transplant improves later risk of diabetes.
6. . “National Diabetes Statistics Report (Centers for Disease Control and Prevention).” Available at: http://www.cdc.gov/diabetes/pubs/statsreport14.htm Retrieved July 11, 2014.
7. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol: WJG. 2009;15:280–8.
8. Russo MJ, Chen JM, Hong KN, et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. Circulation. 2006;114:2280–7.
9. Czerny M, Sahin V, Fasching P, et al. The impact of diabetes mellitus at the time of heart transplantation on long-term survival. Diabetologia. 2002;45:1498–508.
10. Klingenberg R, Gleissner C, Koch A, et al. Impact of pre-operative diabetes mellitus upon early and late survival after heart transplantation: a possible era effect. J Heart Lung Transplant: Off Publ Int Soc Heart Transplant. 2005;24:1239–46.
11. Lang CC, Beniaminovitz A, Edwards N, Mancini DM. Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant: Off Publ Int Soc Heart Transplant. 2003;22:244–9.
12. Dare AJ, Plank LD, Phillips AR, et al. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation. Liver Transplant: Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2014;20:281–90.
13. Younossi ZM, Stepanova M, Saab S, et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40(6):686–94. doi: 10.1111/apt.12881. Impact of diabetes and obesity on liver transplant outcomes.
14. Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis: Off J Natl Kidney Found. 2003;41:480–7.
15. Baum CL. Weight gain and cardiovascular risk after organ transplantation. JPEN J Parenter Enteral Nutr. 2001;25:114–9.
16. Oterdoom LH, de Vries AP, Gansevoort RT, et al. Determinants of insulin resistance in renal transplant recipients. Transplantation. 2007;83:29–35.
17. Chakkera HA, Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol: CJASN. 2009;4:853–9.
18. Kamar N, Mariat C, Delahousse M, et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transpl: Off Publ Eur Dial Transplant Assoc Eur Ren Assoc. 2007;22:1986–93.
19. Pageaux GP, Faure S, Bouyabrine H, Bismuth M, Assenat E. Long-term outcomes of liver transplantation: diabetes mellitus. Liver Transplant: Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2009;15 Suppl 2:S79–82.
20. Sulanc E, Lane JT, Puumala SE, et al. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation. 2005;80:945–52.
21. Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation. 2009;88:429–34.
22. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2007;7:1506–14.
23. Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. Transplantation. 2010;89:1526–32.
24. Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol: JASN. 2010;21:383–5.
25. Mathew JT, Rao M, Job V, Ratnaswamy S, Jacob CK. Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc Eur Ren Assoc. 2003;18:164–71.
26. Mathis AS, Liu MT, Adamson RT, Nambi SS, Patel AM. Retrospective analysis of early steroid-induced adverse reactions in kidney and kidney-pancreas transplant recipients. Transplant Proc. 2007;39:199–201.
27. Johnson JD, Ao Z, Ao P, et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant. 2009;18:833–45.
28. Oetjen E, Baun D, Beimesche S, et al. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol. 2003;63:1289–95.
29. Radu RG, Fujimoto S, Mukai E, et al. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. Am J Physiol Endocrinol Metab. 2005;288:E365–71.
30. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest. 1996;98:2786–93.
31. Sharif A, Shabir S, Chand S, et al. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephro: JASN. 2011;22:2107–18. Impact of calcineurin inhibitor-sparing regimens on post-transplant diabetes.
32. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol: JASN. 2008;19:1411–8.
33. Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc. 2011;43:1583–92. Impact of sirolimus on post-transplant diabetes.
34. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes. 2008;57:945–57.
35. Larsen JL, Bennett RG, Burkman T, et al. Tacrolimus and sirolimus cause insulin resistance in normal Sprague Dawley rats. Transplantation. 2006;82:466–70.
36. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol: JASN. 2005;16:3128–35.
37. Roehl KA, Lach K, Coltman AE, et al. Predictors of insulin requirements among hospitalized adults receiving parenteral nutrition. JPEN J Parenter Enteral Nutr. 2013;37:755–62.
38. O’Keefe SJ, Emerling M, Koritsky D, et al. Nutrition and quality of life following small intestinal transplantation. Am J Gastroenterol. 2007;102:1093–100.
39. Rzepecki P, Barzal J, Oborska S. Blood and marrow transplantation and nutritional support. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer. 2010;18 Suppl 2:S57–65.
40. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4:384–9.
41. Leonidou L, Michalaki M, Leonardou A, et al. Stress-induced hyperglycemia in patients with severe sepsis: a compromising factor for survival. Ame J Med Sci. 2008;336:467–71.
42. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100:48–55.
43. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365–70.
44. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia. 1984;27:351–7.
45. American Diabetes Association. Executive summary: standards of medical care in diabetes—2014. Diabetes Care. 2014;37 Suppl 1: S5-13.
46. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97.
47. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999;67:352–60. discussion 360–352.
48. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314:1512–5.
49. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626–32.
50. Ishihara M, Kojima S, Sakamoto T, et al. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J. 2005;150:814–20.
51. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2003;3:178–85.
52. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact Post-Transplant Diabetes Kidney Int. 2002;62:1440–6.
53. Parekh J, Roll GR, Feng S, Niemann CU, Hirose R. Peri-operative hyperglycemia is associated with delayed graft function in deceased donor renal transplantation. Clin Transpl. 2013;27:E424–30. Impact of perioperative hyperglycemia on graft function after deceased kidney transplant.
54. Parekh J, Niemann CU, Dang K, Hirose R. Intraoperative hyperglycemia augments ischemia reperfusion injury in renal transplantation: a prospective study. J Transplant. 2011;2011:652458. Impact of perioperative hyperglycemia on graft function after kidney transplant.
55. Ganji MR, Charkhchian M, Hakemi M, et al. Association of hyperglycemia on allograft function in the early period after renal transplantation. Transplant Proc. 2007;39:852–4.
56. Wallia A, Parikh ND, Molitch ME, et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010;89:222–6.
57. Thomas MC, Mathew TH, Russ GR, Rao MM, Moran J. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321–4.
58. Thomas MC, Moran J, Mathew TH, Russ GR, Rao MM. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrol. 2000;1:1.
59. Ammori JB, Sigakis M, Englesbe MJ, O’Reilly M, Pelletier SJ. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res. 2007;140:227–33.
60. Hermayer KL, Egidi MF, Finch NJ, et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab. 2012;97:4399–406. Glycemic control and kidney transplant outcomes.
61. van den Berg TJ, Bogers H, Vriesendorp TM, et al. No apparent impact of increased post-operative blood glucose levels on clinical outcome in kidney transplant recipients. Clin Transpl. 2009;23:256–63.
62. Hosseini MS, Nemati E, Pourfarziani V, et al. Early hyperglycemia after allogenic kidney transplantation: does it induce infections. Ann Transplant: Q Pol Transplant Soc. 2007;12:23–6.
63. Park C, Hsu C, Neelakanta G, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation. 2009;87:1031–6.
64. Anderson AL, Lewis DA, Steinke DT, et al. Effects of hyperglycemia on the development of new-onset diabetes after liver transplantation. Prog Transplant. 2009;19:298–303.
65. Keegan MT, Vrchota JM, Haala PM, Timm JV. Safety and effectiveness of intensive insulin protocol use in post-operative liver transplant recipients. Transplant Proc. 2010;42:2617–24.
66. Sanchez-Perez B, Aranda Narvaez JM, Santoyo Santoyo J, et al. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. Transplant Proc. 2008;40:2994–6.
67. Wallia A, Parikh ND, O’Shea-Mahler E, et al. Glycemic control by a glucose management service and infection rates after liver transplantation. Endocr Pract. 2011;17:546–51. Glycemic control and infections after liver tranpslant.
68. Garcia C, Wallia A, Gupta S, et al. Intensive glycemic control after heart transplantation is safe and effective for diabetic and non-diabetic patients. Clin Transpl. 2013;27:444–54. Glycemic control after heart transplant.
69. Wallia A, Gupta S, Garcia C, et al. Examination of implementation of intravenous and subcutaneous insulin protocols and glycemic control in heart transplant patients. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2014;20:527–35. Glycemic control after heart transplant.
70. Rentschler LM, Swarts SJ, Bierman PJ, et al. Association between hyperglycemia and hospital length of stay in patients undergoing hematopoietic stem cell transplantation. Endocrinologist. 2010;20:232–5.
71. Sheean PM, Braunschweig C, Rich E. The incidence of hyperglycemia in hematopoietic stem cell transplant recipients receiving total parenteral nutrition: a pilot study. J Am Diet Assoc. 2004;104:1352–60.
72. Sheean PM, Freels SA, Helton WS, Braunschweig CA. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2006;12:656–64.
73. Fuji S, Kim SW, Mori S, et al. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation. 2007;84:814–20.
74. Gebremedhin E, Behrendt CE, Nakamura R, Parker P, Salehian B. Severe hyperglycemia immediately after allogeneic hematopoietic stem-cell transplantation is predictive of acute graft-versus-host disease. Inflammation. 2013;36:177–85. Hyperglycemia and impact on hematopoietic stem cell transplant.
75. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol: CJASN. 2008;3:814–21.
76. Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol. 2014;2014:617638. Safety of DPP-IV inhibitor in treatment of diabetes after kidney transplant.
77. Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation—a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2013;14:115–23. Safety of DPP-IV inhibitor in treatment of diabetes after kidney transplant.
78. Sanyal D, Gupta S, Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J Endocrinol Metab. 2013;17:S203–5. Safety of DPP-IV inhibitor in treatment of diabetes after kidney transplant.
79. Luther P, Baldwin Jr D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant. 2004;4:2135–8.
80. Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14:979–84.
81. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation. 2008;85:353–8.